natgillin/translations-raw huggingface dataset:
Marking
Peale selle tunnustab teine kokkuleppeosaline partii ametlikku kasutamiseks vabastamist eksportiva kokkuleppeosalise asutuse poolt. „Ravimid“ – kõik käesoleva peatüki I jaos loetletud Euroopa Liidu ja Šveitsi farmaatsiaalaste õigusaktidega reguleeritud tooted.
“CH for Switzerland”.
Käesoleva peatüki kohaldamisel hõlmab see süsteemi, mille kohaselt tootja saab toote ja tootmismeetodite tehnilised nõuded müügiloa omanikult või taotlejalt ning tagab, et ravimit valmistatakse nende tehniliste nõuete kohaselt.
The drawings to which point 3.2.1 of Annex II refers, are supplemented by the following drawing:
Selliste ravimite puhul, mis on hõlmatud ainult ühe kokkuleppeosalise õigusaktidega, võib tootjaettevõte kokkuleppe kohaldamise korral taotleda inspekteerimist kohaliku pädevusega järelevalvetalituse poolt.
By the way of derogation from Article 1 of this Agreement, the rules on marking for measuring instruments placed on the Swiss market are as follows:
Seda sätet kohaldatakse muu hulgas aktiivsete farmatseutiliste koostisosade, vahetoodete ja uuritavate ravimite, samuti turustamiseelsete kontrollimiste suhtes.
The marking that must be affixed is the EC marking and supplementary metrology marking or the national sign of the EC Member State concerned as provided in the first indent of point 3.1 of Annex I and the first indent of point 3.1.1.1 of Annex II to Directive 2009/34/EC of 23 April 2009.
Asjaomast töökorda on üksikasjalikult kirjeldatud III jao lõikes 3.
Non-automatic weighing instruments covered by Directive 2014/31/EU and measuring instruments covered by Directive 2014/32/EU
Tootja sertifitseerimine
Specific obligations of economic operators pursuant to the legislation under Section I
Eksportija, importija või teise kokkuleppeosalise pädeva asutuse taotluse korral tõendavad tootmislubade andmise ja ravimite tootmise järelevalve eest vastutavad asutused, et:
for the purpose of the obligations in Articles 6(6) and 8(3) of Directive 2014/31/EU, respectively Articles 8(6) and 10(3) of Directive 2014/32/EU and the corresponding Swiss provisions, it shall be sufficient to indicate the name, registered trade name or registered trade mark and the postal address at which the manufacturer established within the territory of either the European Union or Switzerland can be contacted.
tootjal on vajalik luba asjaomase ravimi tootmiseks või asjaomase täpsustatud tootmisoperatsiooni tegemiseks;
for the purpose of the obligations in Articles 6(3) and 8(8) of Directive 2014/31/EU, respectively Articles 8(3) and 10(8) of Directive 2014/32/EU and the corresponding Swiss provisions, it shall be sufficient that the manufacturer established within the territory of either the European Union or Switzerland keep the technical documentation and the EU declaration of conformity or, where applicable, the attestation of conformity for 10 years after the instrument has been placed on the market in either the European Union or Switzerland.
ametiasutused kontrollivad tootjat regulaarselt;
In case the manufacturer is not established within the territory of either the European Union or Switzerland, it shall be sufficient that the importer established within the territory of either the European Union or Switzerland keep a copy of the EU declaration of conformity or, where applicable, the attestation of conformity at the disposal of the market surveillance authorities and ensure that the technical documentation can be made available to those authorities upon request for 10 years after the instrument has been placed on the market in either the European Union or Switzerland;
tootja järgib riiklikke hea tootmistava nõudeid, mida kokkuleppeosalised tunnustavad samaväärsetena ja mis on loetletud käesoleva peatüki I jaos.
for the purpose of the obligations in Articles 6(4), second subparagraph, and 8(6) of Directive 2014/31/EU, respectively Articles 8(4), second subparagraph, and 10(6) of Directive 2014/32/EU and the corresponding Swiss provisions, it shall be sufficient that such obligations be fulfilled by the manufacturer established within the territory of either the European Union or Switzerland, or, in case the manufacturer is not established within the territory of either the European Union or Switzerland, by the importer established within the territory of either the European Union or Switzerland.
Kui viitena kasutatakse muid hea tootmistava nõudeid, tuleb seda sertifikaadis mainida.
For the purpose of the obligation in Article 7(2) of Directive 2014/31/EU, respectively Article 9(2) of Directive 2014/32/EU and the corresponding Swiss provisions, authorised representative shall mean any natural or legal person established within the European Union or Switzerland who has received a written mandate from a manufacturer to act on his behalf pursuant to Article 7(1) of Directive 2014/31/EU, respectively Article 9(1) of Directive 2014/32/EU or the corresponding Swiss provisions.
Kolmandates riikides toimuvate kontrollimiste puhul tõendavad kontrollimise eest vastutavad asutused eksportija, importija või teise kokkuleppeosalise pädeva asutuse taotluse korral, kas tootja vastab või ei vasta hea tootmistava nõuetele, mida kaks kokkuleppeosalist tunnustavad samaväärsetena ja mis on loetletud käesoleva peatüki I jaos.
The competent national market surveillance authority of a Member State of the European Union or Switzerland may, on reasoned request, ask the relevant economic operators in the European Union and in Switzerland to provide all the information and documentation necessary to demonstrate the conformity of instrument with the legislation in Section I.
Sertifikaadis märgitakse ka tootmise asukoht/asukohad (ja olemasolu korral lepingu alusel töötavad kvaliteedikontrollimise laborid) ning kontrollimise kuupäev.
It may request the economic operators to cooperate on any action taken to eliminate the risks posed by the instrument.
Sertifikaat väljastatakse viivitamata ning selleks ei tohi kuluda rohkem kui 30 kalendripäeva.
Swiss designating authorities may take part in the exchange of experience between the Member States' national authorities referred to in Article 34 of Directive 2014/31/EU and Article 39 of Directive 2014/32/EU.
Erandjuhtudel, st kui on vaja teha uus kontrollimine, võib seda ajavahemikku pikendada 90 päevani.
Swiss designated conformity assessment bodies may take part in the coordination and cooperation mechanisms provided for in Article 35 of Directive 2014/31/EU, respectively Article 40 of Directive 2014/32/EU, directly or by means of designated representatives.
Partii sertifitseerimine
Procedure for dealing with instruments presenting a risk caused by non-compliance not restricted to the national territory
Iga eksporditud partiiga on kaasas partiisertifikaat (tootja tõend), mille tootja on koostanud pärast täielikku kvalitatiivset analüüsi, kõigi toimeainete kvantitatiivset analüüsi ning kõiki muid katseid ja kontrollimisi, mis on vajalikud toote müügiloa nõuetele vastava kvaliteedi tagamiseks.
Pursuant to Article 12(4) of this Agreement, where the market surveillance authorities of a Member State or Switzerland have taken action or have sufficient reason to believe that an instrument covered by this chapter presents a risk to aspects of public interest protection covered by Directive 2014/31/EU or Directive 2014/32/EU, or the corresponding Swiss provisions, and if they consider that non-compliance is not restricted to their national territory, they shall inform the European Commission, the other Member States and Switzerland without delay of:
Selle sertifikaadiga tõendatakse, et partii vastab tehnilistele nõuetele, ning see jääb toote importija kätte.
where the relevant economic operator does not take adequate corrective action, all appropriate provisional measures taken to prohibit or restrict the instrument's being made available on their national market, to withdraw the instrument from that market or to recall it.
Sertifikaat esitatakse pädeva asutuse taotlusel.
This information shall include all available details, in particular the data necessary for the identification of the non-compliant instrument, the origin of the instrument, the nature of the non-compliance alleged and the risk involved, the nature and duration of the national measures taken and the arguments put forward by the relevant economic operator.
Sertifikaati väljastades võtab tootja arvesse Maailma Tervishoiuorganisatsiooni (WHO) kehtiva rahvusvahelises kaubanduses ringluses olevate farmaatsiatoodete sertifitseerimiskava sätteid.
failure of the instrument to meet requirements relating to aspects of public interest protection laid down in Directive 2014/31/EU or Directive 2014/32/EU, or the corresponding Swiss provisions, or
Sertifikaadis kirjeldatakse üksikasjalikult toote kokkulepitud tehnilisi nõudeid, analüütiliste meetodite võrdlust ning analüüside tulemusi.
shortcomings in the harmonised standards referred to in Directive 2014/31/EU or Directive 2014/32/EU, or the corresponding Swiss provisions.
Sertifikaat hõlmab ka avaldust selle kohta, et partii töötlemise ja pakendamisega seotud dokumendid on läbi vaadatud ning vastavad heale tootmistavale.
Switzerland, or Member States shall without delay inform the European Commission and the other national authorities of any measures adopted and of any additional information at their disposal relating to the non-compliance of the instrument concerned.
Partiisertifikaadile kirjutab alla isik, kes vastutab partii ringlusselaskmise eest müümiseks või tarnimiseks, st Euroopa Liidus direktiivi 2001/83/EÜ artiklis 48 ja direktiivi 2001/82/EÜ artiklis 52 osutatud „asjatundja“ ning Šveitsis asutamislitsentse käsitleva määruse artiklites 5 ja 10 osutatud „vastutav isik“.
Member States and Switzerland shall ensure that appropriate restrictive measures are taken in respect of the instrument concerned, such as withdrawal of an instrument from their market, without delay.
Partii ametlik kasutamiseks vabastamine
Should it disagree with the notified national measure, Switzerland or a Member State shall inform the European Commission of its objections within three months of the receipt of the information.
Partii ametliku kasutamiseks vabastamise menetluse kohaldamise korral tunnustab teine kokkuleppeosaline partii ametlikku kasutamiseks vabastamist eksportiva kokkuleppeosalise asutuse (loetletud II jaos) poolt.
Where, on completion of the procedure set out in paragraph 3.4, objections are raised by a Member State or Switzerland against a measure taken by Switzerland or a Member State or where the Commission considers a national measure to be contrary to Directive 2014/31/EU or Directive 2014/32/EU, or the corresponding Swiss provisions, the European Commission shall without delay enter into consultation with the Member States, Switzerland, and via the Swiss authorities the relevant economic operator or operators.
Tootja esitab partii ametliku kasutamiseks vabastamise sertifikaadi.
If the national measure relating to an instrument is considered:
Euroopa Liidu puhul on partiide ametliku kasutamiseks vabastamise menetlust kirjeldatud dokumendis „Vaktsineerimistoodete ja verepreparaatide partiide kasutamiseks vabastamine kontrolliasutuste poolt.
justified, all Member States and Switzerland shall take the measures necessary to ensure that the non-compliant instrument is withdrawn from their markets, and shall inform the Commission accordingly,
2001“ või sellele järgnevates versioonides ja erinevates konkreetsetes partiide kasutamiseks vabastamise menetlustes.
A Party may forward the issue to the Committee established under Article 10 of this Agreement, pursuant to paragraph 3.8.
Šveitsi puhul on partiide ametliku kasutamiseks vabastamise menetlust kirjeldatud ravimeid ja meditsiiniseadmeid käsitleva föderaalseaduse artiklis 17 ja Šveitsi ravimiameti ravimite müügilubade nõudeid käsitleva määruse artiklites 18–21.
Compliant instruments which nevertheless present a risk to health and safety
Euroopa Parlamendi ja nõukogu 31. märtsi 2004. aasta määrus (EÜ) nr 726/2004, milles sätestatakse ühenduse kord inim- ja veterinaarravimite lubade andmise ja järelevalve kohta ning millega asutatakse Euroopa ravimiamet (ELT L 136, 30.4.2004, lk 1), viimati muudetud Euroopa Parlamendi ja nõukogu 25. oktoobri 2012. aasta määrusega (EL) nr 1027/2012, millega muudetakse seoses ravimiohutuse järelevalvega määrust (EÜ) nr 726/2004 (ELT L 316, 14.11.2012, lk 38).
Where a Member State or Switzerland finds that, although an instrument that an economic operator has been made available on the EU and on the Swiss market is in compliance with Directive 2014/31/EU or Directive 2014/32/EU, respectively the relevant Swiss legislation, presents a risk to aspects of public interest protection, it shall take all appropriate measures and immediately inform the Commission, other Member States and Switzerland.
Euroopa Parlamendi ja nõukogu 6. novembri 2001. aasta direktiiv 2001/83/EÜ inimtervishoius kasutatavaid ravimeid käsitlevate ühenduse eeskirjade kohta (EÜT L 311, 28.11.2001, lk 67), viimati muudetud Euroopa Parlamendi ja nõukogu 25. oktoobri 2012. aasta direktiiviga 2012/26/EL, millega muudetakse seoses ravimiohutuse järelevalvega direktiivi 2001/83/EÜ (ELT L 299, 27.10.2012, lk 1).
That information shall include all available details, in particular the data necessary for the identification of the instrument concerned, the origin and the supply chain of the instrument, the nature of the risk involved and the nature and duration of the national measures taken.
Euroopa Parlamendi ja nõukogu 27. jaanuari 2003. aasta direktiiv 2002/98/EÜ, millega kehtestatakse inimvere ja verekomponentide kogumise, uurimise, töötlemise, säilitamise ja jaotamise kvaliteedi- ja ohutusnõuded ning muudetakse direktiivi 2001/83/EÜ (ELT L 33, 8.2.2003, lk 30).
In case of a disagreement between the Parties on measures at stake in subparagraphs 3.6 and 3.7 above, the issue will be forwarded to the Committee, which will decide on an appropriate course of action, including the possibility to have an expert study carried out.
Euroopa Parlamendi ja nõukogu 6. novembri 2001. aasta direktiiv 2001/82/EÜ veterinaarravimeid käsitlevate ühenduse eeskirjade kohta (EÜT L 311, 28.11.2001, lk 1), viimati muudetud Euroopa Parlamendi ja nõukogu 18. juuni 2009. aasta direktiiviga 2009/53/EÜ, millega muudetakse direktiivi 2001/82/EÜ ja direktiivi 2001/83/EÜ seoses ravimite müügilubade tingimuste muutmisega (ELT L 168, 30.6.2009, lk 33).
justified, the Parties shall take the measures necessary to ensure that the instrument is withdrawn from their market;
Komisjoni 8. oktoobri 2003. aasta direktiiv 2003/94/EÜ, millega kehtestatakse inimestele mõeldud ravimite ning inimestele mõeldud uuritavate ravimite hea tootmistava põhimõtted ja suunised (ELT L 262, 14.10.2003, lk 22).
ATTACHMENT G
Komisjoni 23. juuli 1991. aasta direktiiv 91/412/EMÜ, millega kehtestatakse veterinaarravimite hea tootmistava põhimõtted ja suunised (EÜT L 228, 17.8.1991, lk 70) ja nõukogu 26. märtsi 1990. aasta direktiiv 90/167/EMÜ, millega kehtestatakse ravimsöötade ühenduses valmistamise, turuleviimise ja kasutamise tingimused (EÜT L 92, 7.4.1990, lk 42).
In Annex 1, Product Sectors, Chapter 15, Medicinal products, GMP Inspection and Batch Certification should be deleted and replaced by the following:
Suunised inimtervishoius kasutatavate ravimite hea turustamistava kohta (ELT C 343, 23.11.2013, lk 1).
‘CHAPTER 15
EudraLexi 4. number — Medicinal Products for Human and Veterinary Use:
MEDICINAL PRODUCTS, GMP INSPECTION AND BATCH CERTIFICATION
EU Guidelines to Good Manufacturing Practice (Inimtervishoius kasutatavad ravimid ja veterinaarravimid: ELi hea tootmistava juhend) (avaldatud Euroopa Komisjoni veebisaidil)
Scope and coverage
4. aprilli 2001. aasta direktiiv 2001/20/EÜ liikmesriikide õigus- ja haldusnormide ühtlustamise kohta, mis käsitlevad hea kliinilise tava rakendamist inimtervishoius kasutatavate ravimite kliinilistes uuringutes (EÜT L 121, 1.5.2001, lk 34) ning Euroopa Parlamendi ja nõukogu 16. aprilli 2014. aasta määrus (EL) nr 536/2014, milles käsitletakse inimtervishoius kasutatavate ravimite kliinilisi uuringuid ja millega tunnistatakse kehtetuks direktiiv 2001/20/EÜ (ELT L 158, 27.5.2014, lk 1).
The provisions of this Sectoral Chapter cover all medicinal products which are industrially manufactured and to which Good Manufacturing Practice (GMP) requirements apply.
Komisjoni 8. aprilli 2005. aasta direktiiv 2005/28/EÜ, millega kehtestatakse inimtervishoius kasutatavate uuritavate ravimite hea kliinilise tava põhimõtted ja suunised ning nõuded nimetatud ravimite tootmis- ja impordilubadele (ELT L 91, 9.4.2005, lk 13).
For medicinal products covered by this Chapter, each party shall recognise the conclusions of inspections of manufacturers carried out by the relevant inspection services of the other Party and the relevant manufacturing authorisations granted by the competent authorities of the other Party.
Komisjoni 28. mai 2014. aasta delegeeritud määrus (EL) nr 1252/2014, millega täiendatakse Euroopa Parlamendi ja nõukogu direktiivi 2001/83/EÜ seoses inimtervishoius kasutatavate ravimite toimeainete head tootmistava käsitlevate põhimõtete ja suunistega (ELT L 337, 25.11.2014, lk 1).
This includes that each Party recognises conclusions of inspections of manufacturers in third countries carried out by the relevant inspection services of the other Party, inter alia, within the framework of the European Directorate for the Quality of Medicines & HealthCare (EDQM).
15. detsembri 2000. aasta föderaalseadus ravimite ja meditsiiniseadmete kohta (RO 2001 2790), viimati muudetud 1. jaanuaril 2014 (RO 2013 4137)
The Parties shall cooperate in order to achieve the best use of inspection resources by an appropriate burden sharing.
17. oktoobri 2001. aasta määrus litsentside väljastamise kohta (RO 2001 3399), viimati muudetud 1. mail 2016 (RO 2016 1171)
The manufacturer's certification of the conformity of each batch to its specifications shall be recognised by the other Party without re-control at import.
Šveitsi ravimiameti 9. novembri 2001. aasta määrus ravimite müügilubade nõuete kohta (RO 2001 3437), viimati muudetud 1. mail 2016 (RO 2016 1171)
To the products imported from a third country and further exported to the other Party this provision applies only (1) if each batch of the medicinal products has been subject to the re-control in the territory of one of the Parties; and (2) if the manufacturer in the third country has been subject to the inspection by the competent authority of either Party of which the outcome has been that for the products or products category the manufacturer complies with Good Manufacturing Practice.
20. septembri 2013. aasta määrus kliiniliste katsete kohta inimuuringutes (RO 2013 3407), viimati muudetud 1. mail 2017 (RO 2017 2439)
If the above conditions are not met, each Party can require a re-control in its territory.
Käesoleva peatüki kohaldamisel tähendab termin „vastavushindamisasutused“ kummagi kokkuleppeosalise ametlikke hea tootmistava järelevalvetalitusi.
In addition, official batch releases carried out by an authority of the exporting Party will be recognised by the other Party.
Euroopa Liidu liikmesriikide ja Šveitsi ametlike hea tootmistava järelevalvetalituste loetelu on esitatud allpool.
“Medicinal products” means all products regulated by pharmaceutical legislation in the European Union and Switzerland as listed in Section I of this Chapter.
Euroopa Liidu vastavushindamisasutused
The definition of medicinal products includes all human and veterinary products, such as chemical and biological pharmaceuticals, immunologicals, radio-pharmaceuticals, stable medicinal products derived from human blood or human plasma, pre-mixes for the preparation of veterinary medicated feedingstuffs and, where appropriate, vitamins, minerals, herbal remedies and homeopathic medicinal products.
Euroopa Liidu pädevad asutused on järgmised Euroopa Liidu liikmesriikide ametiasutused või nende õigusjärglased:
“GMP” is that part of quality assurance which ensures that products are consistently produced and controlled to the quality standards appropriate to their intended use and as required by the marketing authorisation and products specifications.
Riik
For the purpose of this Chapter it includes the system whereby the manufacturer receives the specification of the product and the process from the marketing authorisation holder or applicant and ensures that the medicinal product is made in compliance with this specification.
Inimravimid
With respect to medicinal products covered by the legislation of one Party but not the other, the manufacturing company can request, for the purpose of this Agreement, an inspection be made by the locally competent inspection service.
Veterinaarravimid
This provision shall apply i.a. to the manufacture of active pharmaceutical ingredients, intermediate products and investigational medicinal products, as well as to pre-marketing inspections.
Austria tervise- ja toiduohutuse amet/Österreichische Agentur für Gesundheit und Ernährungssicherheit GmbH
Operational arrangements are detailed under Section III, paragraph 3.
Vt inimravimite eest vastutav asutus
At the request of an exporter, importer or the competent authority of the other Party, the authorities responsible for granting manufacturing authorisations and for supervision of the manufacture of medicinal products shall certify that the manufacturer:
Ravimite ja tervisetoodete föderaalne asutus/Federaal Agentschap voor geneesmiddelen en gezondheidsproducten/Agence fédérale des médicaments et produits de santé
is appropriately authorised to manufacture the relevant medicinal product, or to carry out the relevant specified manufacturing operation,
Bulgaaria
is regularly inspected by the authorities,
Bulgaaria ravimiamet/
complies with the national GMP requirements recognised as equivalent by the two parties, and which are listed in Section I of this Chapter.
Bulgaaria toiduohutusamet/
Should different GMP requirements be used as reference, this is to be mentioned in the certificate.
Küpros
For inspections in third countries, at the request of an exporter, importer or the competent authority of the other Party, the authorities responsible for the inspection shall certify that the manufacturer complies or does not comply with the GMP requirements recognised as equivalent by the two Parties, and which are listed in Section I of this Chapter.
Tervishoiuministeerium – ravimiteenistus/
The certificates shall also identify the site(s) of manufacture (and contract quality control laboratories, if any) and the date of the inspection.
Põllumajandus-, maaelu arendamise ja keskkonnaministeerium – veterinaarteenistus/
Certificates shall be issued expeditiously, and the time taken should not exceed 30 calendar days.
Tšehhi
In exceptional cases, i.e. when a new inspection has to be carried out, this period may be extended to 90 days.
Ravimikontrolli riiklik instituut/
Batch certification
Bioloogiliste veterinaarravimite ja veterinaarravimite riikliku kontrolli instituut/
Each batch exported shall be accompanied by a batch certificate established by the manufacturer (self-certification) after a full qualitative analysis, a quantitative analysis of all the active ingredients and all the other tests or checks necessary to ensure the quality of the product in accordance with the requirements of the marketing authorisation.
Horvaatia
This certificate shall attest that the batch meets its specifications and shall be kept by the importer of the batch.
Ravimite ja meditsiiniseadmete amet/
When issuing a certificate, the manufacturer shall take account of the provisions of the current WHO certification scheme on the quality of pharmaceutical products moving in international commerce.
Taani
The certificate shall detail the agreed specifications of the product, the reference of the analytical methods and the analytical results.
Taani ravimiamet/